While the world obsesses over AI food delivery apps, Cambridge Allergy has built a £2.7M revenue engine in the unglamorous but critical world of clinical allergy testing. This isn't a Silicon Valley story—it's a £2.7M revenue business operating from a quiet corner of the UK, solving a problem that affects 1 in 3 children. The question isn't whether they'll scale, but why they've stayed so stealth for so long.

"This isn't a growth story—it's a precision instrument. They're not chasing traffic; they're curing conditions."

The team composition reveals everything. With two medical co-founders (Pamela Ewan and Andrew Clark) plus a CFO consultant, this is a clinical-first operation. The technology stack—Squarespace, Tailwind, Bootstrap—screams 'functional, not flashy.' They're not building an app; they're building trust. The absence of social profiles and Trustpilot reviews isn't neglect—it's a deliberate strategy. Medical validation happens in clinics, not on Twitter.

• Revenue per employee: £117K—exceptional for a UK med-tech startup
• Traffic quality over quantity: 100% UK-focused traffic (no global dilution)
• The 'Cambridge' brand is their moat: Medical professionals trust the name
• No funding listed means they're bootstrapped or privately held—unusual for this scale